Investigational drug · Phase 3
Tarcocimab
Also called: Tarcocimab tedromer, KSI-301
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Wet Age-related Macular Degeneration, Diabetic Retinopathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Tarcocimab"
First trial start
2024
May 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tarcocimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wet Age-related Macular Degeneration
- Diabetic Retinopathy
Approved drugs for the same conditions: Wet macular degeneration · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tarcocimab" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPivotal-lookingActive, not recruiting
Kodiak Sciences IncIndustry
NCT06556368 · 667 participants · Start Aug 23, 2024 · Primary completion Sep 2, 2026
Drug: Tarcocimab tedromer; Tabirafusp tedromer and 1 more · For: Wet Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 72 sites in all
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)Pivotal-lookingCompleted
Kodiak Sciences IncIndustry
NCT06270836 · 255 participants · Start May 1, 2024 · Primary completion Feb 13, 2026
Drug: Tarcocimab · For: Diabetic Retinopathy
Sites: Tucson, Arizona; Fullerton, California; Glendale, California · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
- Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability.
Stewart MW · Expert Opin Drug Metab Toxicol 2024
- Perspectives on the currently available pharmacotherapy for wet macular degeneration.
Kumar A, Ferro Desideri L, Ting MYL, et al. · Expert Opin Pharmacother 2024
- Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration.
Kaiser PK, Giani A, Fuchs H, et al. · Ophthalmic Res 2023
- Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ, Tolentino AJ · Expert Opin Investig Drugs 2022
Also in development for Wet Age-related Macular Degeneration
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- EXG202Phase 21 trial
Guangzhou Jiayin Biotech Ltd · Wet Age-related Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.